DVHGF (Devonian Health Group) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DVHGF Devonian Health Group Inc DVHGF
53 GF Score
Price $7.00
GF Value $2.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group SpecialCharges?

Special Charges only applies to banks.

DVHGF
53GF Score
Devonian Health Group Inc DVHGF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 213.9% above its estimated GF Value™ of $2.23. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

  • SpecialCharges:
  • GF Value™: $2.23 vs. price of $7.00 (213.9% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
53GF Score

Get the complete analysis for DVHGF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$2.23
GF Value